For the Q2 2026 reporting period, BioLineRx is expected to post revenue of $0.50 million and a break-even EPS of $0.00, as the stock trades at $2.60 against a significantly higher analyst price target of $17.50.
The central focus for shareholders remains the royalty income generated from APHEXDA sales under the partnership with Ayrmid.
BioLineRx recently transitioned to a development-focused model, utilizing a $3.75 million share offering to fund its Phase 1/2a GLIX1 clinical trial for glioblastoma. While royalty revenues grew 66% year-over-year in the prior quarter, investors are assessing if this growth is sufficient to sustain the company's clinical pipeline through 2027.